MiMedx Group (MDXG) Projected to Post Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is projected to issue its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.0003 per share and revenue of $68.56 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. On average, analysts expect MiMedx Group to post ($0.10) EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

MiMedx Group Stock Down 1.5%

Shares of NASDAQ:MDXG opened at $3.85 on Tuesday. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $4.52 and its 200 day moving average is $4.34. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.97. The stock has a market cap of $561.18 million, a price-to-earnings ratio of 96.27 and a beta of 1.18.

Wall Street Analyst Weigh In

A number of research firms have commented on MDXG. Cantor Fitzgerald reissued an “overweight” rating on shares of MiMedx Group in a research note on Tuesday, September 15th. Seaport Research Partners downgraded MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Raymond James Financial set a $8.00 target price on MiMedx Group in a research report on Monday, August 17th. Wall Street Zen upgraded MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, August 27th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.57.

About MiMedx Group

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.